Recently approved by FDA, Absorb™ bioresorbable vascular scaffold opens
clogged arteries to restore blood flow, and then gradually dissolves in the body—reducing the risk of future blockages that can occur with metal stents
Los Angeles (July 12, 2016) – Good Samaritan Hospital is the first
hospital on the West Coast to offer patients with coronary artery disease
(CAD) a first-of-its-kind dissolving heart stent. Abbott’s Absorb™
dissolving heart stent is a drug eluting coronary stent that dissolves,
completely and naturally, in the body over time. Absorb™ treats
coronary artery disease like a metallic stent, propping the diseased vessel
open to restore blood flow, but then disappears after the artery is healed, leaving no
metal behind to restrict natural vessel motion.
Steven Burstein, MD, interventional cardiologist and medical director of
the Cardiac Catherization Laboratory at Good Samaritan Hospital, is the
first on the West Coast to implant the Absorb™ dissolving stent
to patient Ernest Matson, 69, a retired Microbiology professor from the
University of Guam on July 11th.
According to the National Heart, Lung and Blood Institute, CAD is the most
common type of heart disease. CAD is a condition in which the arteries
that supply blood to the heart become narrowed or blocked by a buildup
of “plaque.” Plaque is made up of fat, cholesterol, calcium
and other deposits that accumulate on the inner wall of the artery. Over
time, the plaque hardens and narrows the coronary arteries, limiting the
flow of oxygen-rich blood to the heart muscle. Areas of plaque can also
rupture, causing a blood clot to form on the surface of the plaque. When
blood flow to the heart is reduced or blocked, angina (chest pain) or
a heart attack can occur.
While stents are traditionally made of metal, Abbott’s Absorb™
stent is made of a naturally dissolving material, similar to dissolving
sutures. Absorb™ disappears completely in about 3 years, after it
has done its job of keeping a clogged artery open and promoting healing
of the treated artery segment. By contrast, metal stents are permanent implants.
“With outcomes equivalent to those of the best drug eluting metallic
stents, the Absorb scaffolding will dissolve within 18 to 24 months leaving
behind a normal and natural vessel,” says Dr. Burstein. “This
will not preclude further stenting or bypass surgery and may in fact make
these future procedures, if indicated, easier to perform.”
Absorb™ has been used to treat more than 150,000 people and is available
in more than 100 countries worldwide. It received European regulatory
approval in 2010 and approval from the U.S. Food and Drug Administration in 2016.
 Absorb improves coronary luminal diameter, restores blood flow and enables
movement of the treated vessel. Source: Absorb GT1 IFU.